This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-12 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
== Function == Nicotinamide adenine dinucleotide, is a coenzyme found in all cells. It is produced by nicotinamide-nucleotide adenylyltransferase, which combines adenosine triphosphate and nicotinamide mononucleotide, with inorganic pyrophosphate (PPi) produced as a byproduct:
Reptiles endemic to Somalia include the Hughes' saw-scaled viper, the Southern Somali garter snake, a racer (Platyceps messanai), a diadem snake (Spalerosophis josephscorteccii), the Somali sand boa, the angled worm lizard, a spiny-tailed lizard (Uromastyx macfadyeni), Lanza's agama, a gecko (Hemidactylus granchii), the Somali semaphore gecko, and a sand lizard (Mesalina or Eremias). A colubrid snake (Aprosdoketophis andreonei) and Haacke-Greer's skink (Haackgreerius miopus) are endemic species.
Hamburger, Cheeseburger, Double Cheeseburger, Triple Cheeseburger Big Hit (Big Mac) and Double Big Hit Grand Burger (Quarter Pounder with Cheese / McRoyal), Double Grand Burger, Grand Deluxe Burger (Quarter Pounder with Cheese Deluxe), Grand Deluxe jalapeño Big Special (Big Tasty), Double Big Special, Big Special Junior, Big Special with Mushrooms and Big Chicken Burger (Big Tasty Chicken) Fishburger (Filet-O-Fish) and Double Fishburger Chickenburger (Junior Chicken), Chicken Hit (McChicken), Chicken Hit, Chicken Premier (Seriously Chicken) and Chicken Premier with Mushrooms Caesar Roll (McWrap), Big Special Roll, Shrimp Roll, Fresh Roll and Chicken Fresh Roll French Fries / Grand Fries, Potato wedges and Potato slices Chicken nuggets, chicken strips, Fish Sticks, shrimp, apple slices and carrot sticks Vegetable salad, Caesar salad and Caesar salad with shrimp Dobry Cola (Coca-Cola), Dobry Cola Zero Sugar (Coca-Cola Zero Sugar), Dobry Orange (Fanta), Dobry Lemon-Lime (Sprite), Lipton Ice Tea Lemon, Lipton Ice Tea Green, Lemonade Strawberry-Cactus, Sunrise Strawberry-Cactus, milkshake, sundae, Ice Deluxe (McFlurry), tea, coffee and juice Kids Combo (Happy Meal) Breakfast pancakes, omelet, cherry pie and mango-passion fruit pie
Sources: en.wikipedia.org
Alkyl amines characteristically feature tetrahedral nitrogen centers. C-N-C and C-N-H angles are near 109°. C-N distances are slightly shorter than C-C distances. The energy barrier for the nitrogen inversion of the stereocenter is about 7 kcal/mol for a trialkylamine. The interconversion has been compared to the inversion of an open umbrella into a strong wind. Amines of the type NHRR' and NRR′R″ are chiral: the nitrogen center bears four substituents counting the lone pair. Because of the low barrier to inversion, amines of the type NHRR' cannot be obtained in optical purity. For chiral tertiary amines, NRR′R″ can only be resolved when the R, R', and R″ groups are constrained in cyclic structures such as N-substituted aziridines (quaternary ammonium salts are resolvable).
A highly divisive figure, Gaddafi dominated Libya's politics for four decades and was the subject of a pervasive cult of personality. He was decorated with various awards and praised for his anti-imperialist stance, support for Arab—and then African—unity, as well as for significant development to the country after the discovery of oil reserves. Conversely, many Libyans strongly opposed Gaddafi's social and economic reforms; he was accused of various human rights violations. He was condemned by many as a dictator whose authoritarian administration systematically violated human rights and financed terrorism in the region and abroad.
== Awards and recognition == 1997: Newcomb Cleveland Prize 1998: W. Alden Spencer Award 1999: Albert Lasker Basic Medical Research Award 2000: Rosenstiel Award 2001: Gairdner Foundation International Award 2003: Louisa Gross Horwitz Prize 2003: Nobel Prize in Chemistry
== Limitations of model == AIDA, like other model-based approaches, is not sufficiently accurate to be used for individual patient simulation or glycemic prediction. Therefore, as the program makes clear, it is not intended for insulin therapy planning and can only be used for teaching, self-learning, demonstration, or research purposes. While the AIDA software can simulate a wide variety of insulin dosage and diet (nutrition) adjustments, it should be stressed that the purpose of AIDA is to create a learning environment for communicating and training intuitive thinking when dealing with such adjustments. In this respect AIDA appears most of use for recreating clinical situations in diabetes care, rather than trying to predict best outcome.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.